免疫疗法
肿瘤微环境
基质
胰腺癌
免疫系统
癌症研究
癌症
胰腺导管腺癌
生物
腺癌
临床试验
免疫学
医学
肿瘤科
内科学
生物信息学
免疫组织化学
作者
Jiaqiao Fan,Mengfei Wang,Hailong Chen,Dong Shang,Jugal Kishore Das,Jianxun Jim Song
标识
DOI:10.1186/s12943-020-01151-3
摘要
Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection. Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially improved over the past decades, and impressive results have been obtained in recent preclinical and clinical trials. However, PDAC is likely the exception because of its unique tumour microenvironment (TME). In this review, we summarize the characteristics of the PDAC TME and focus on the network of various tumour-infiltrating immune cells, outlining the current advances in PDAC immunotherapy and addressing the effect of the PDAC TME on immunotherapy. This review further explores the combinations of different therapies used to enhance antitumour efficacy or reverse immunodeficiencies and describes optimizable immunotherapeutic strategies for PDAC. The concordant combination of various treatments, such as targeting cancer cells and the stroma, reversing suppressive immune reactions and enhancing antitumour reactivity, may be the most promising approach for the treatment of PDAC. Traditional treatments, especially chemotherapy, may also be optimized for individual patients to remodel the immunosuppressive microenvironment for enhanced therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI